Lincoln Pharmaceuticals is a family-run branded generics maker that has spent four decades turning a simple idea - “Healthcare for All” - into a factory-to-pharmacy machine that reaches patients in more than 60 countries. Founded in 1979 by the Patel family and listed on Indian exchanges since the mid-1990s, the company has grown from a small enterprise into a vertically integrated operation with over 600 formulations, two manufacturing plants in Gujarat, and an in-house R&D centre that files its own patents. The recurring approach is to own the whole chain - develop the molecule, make the medicine in internationally certified plants, register it in dozens of countries, and then sell it through a dedicated field force or direct export relationships - so that quality, cost and speed stay under one roof. # Business segments A single engine with two customer routes - a domestic branded-generics business that sells acute and chronic medicines to Indian doctors and chemists, and an export arm that ships the same factory output to over 60 countries through branded sales and contract manufacturing - both fed by the same R&D and manufacturing backbone. ## 1. Domestic branded generics: the doctor-led Indian prescription business **A field force of over 700 people calls on more than 30,000 doctors and chemists, pushing a portfolio of over 600 formulations across 15 therapy areas - and the company owns the brands, not just the factory.** - **Organised by disease, not just by product** - the domestic business is split into five named divisions, each targeting a specific set of conditions: Sentinel for chronic lifestyle diseases such as diabetes and hypertension, Flagship for common ailments like colds and pain, Lord’s for diabetes and malaria, Teresa exclusively for women’s health, and Nextgen for skin conditions including fungal infections and cosmeceuticals. - **A flagship brand in a niche** - the company is one of India’s brand leaders in the ENT (ear, nose and throat) segment with its product “Tinnex,” a molecule used for tinnitus relief, which gives it a defensible position in a specialised corner of the acute market. - **First-to-India delivery formats** - it has introduced several novel drug delivery systems as first-time products in the country, including an anti-fungal vaginal spray, a diclofenac rectal spray, a sildenafil oral spray, an ondansetron hydrochloride oral spray, and a programmed-release paracetamol tablet, which help differentiate its offerings in a crowded generics market. - **Reach without owning the shelf** - distribution runs through more than 21 super stockists who feed over 50,000 retail chemists across 26 states, so the company covers the country without carrying the cost of a direct-to-pharmacy logistics fleet. - **One contract-manufacturing exception** - the domestic unit does not manufacture for other pharmaceutical companies, with the sole exception of a single product made for Abbott, keeping the plants focused on Lincoln’s own brands. ## 2. International exports and contract manufacturing: the regulated-market gateway **The same Gujarat factories that supply the domestic market also ship branded generics and contract-manufactured products to over 60 countries - and EU-GMP certification opens the door to all 27 EU member states.** - **Two revenue streams, one export engine** - the international business earns both by selling Lincoln’s own branded generics abroad and through CMO/CDMO (contract manufacturing and development) agreements for regulated markets such as Canada, Australia and the EU, with around 24-25 CDMO projects in the pipeline as of late 2025. - **Registrations are the entry ticket** - the company holds more than 1,500 product registrations across Africa, Latin America, Southeast Asia and parts of the GCC, and each registration represents a legal right to sell a specific medicine in a specific country, built on the dossiers prepared by its in-house R&D team. - **From B2B trading to direct marketing** - until 2021 the export business was largely B2B with country managers promoting products informally; since then the company has put roughly 30-35 people on the ground in various regions to market directly, giving it more control over pricing and brand positioning. - **Canada as the latest proof point** - 15-17 products have already been commercialised in Canada through a CDMO/CMO project, demonstrating that the plants can meet the standards of a stringent regulated market and providing a template for expansion into other EU countries. - **Tenders add a lumpy but reliable layer** - the company has been awarded a number of global institutional tenders, which provide large-volume orders that complement the steady flow of branded and contract sales. # Manufacturing and quality infrastructure **Two plants in Gujarat, one certified by EU-GMP and Australia’s TGA, the other a dedicated cephalosporin facility - and both run on nearly 100% renewable power.** - **Plant 1 at Khatraj: the multi-format workhorse** - this facility makes non-beta-lactam tablets, capsules, ointments, creams, dry-powder suspensions, sterile ophthalmic ointments, injectables, oral liquids, dry-powder injections, and eye and ear drops, and holds EU-GMP, TGA (Australia), WHO-GMP and multiple ISO certifications, which together grant marketing rights across the EU, the European Economic Area and Australia. - **Plant 2 at Mehsana: the cephalosporin specialist** - acquired in September 2021 and funded entirely from internal cash, this dedicated plant was designed to PIC/S and European Region standards and makes cephalosporin tablets, capsules, dry syrup and injectables, initially for the domestic market, and has already obtained WHO-GMP certification for its oral solid and dry-powder products; total investment in the plant is ₹30 crore including capacity expansion. - **Supplier advances that cut raw-material costs** - the company provides advances to raw-material and packing-material suppliers to secure discounts of 2-10%, which lowers the cost of goods sold without compromising quality. - **Energy independence** - in FY 2023-24, the company installed a 4 MW solar plant in Radhanpur, adding to its 1 MW rooftop solar unit and two wind turbines; these initiatives now supply nearly 100% of the company’s energy needs, insulating it from grid-price volatility. # Research and development **A DSIR-approved centre with over 75 professionals develops new formulations, runs bioequivalence studies, and compiles regulatory dossiers - all in-house, so the company does not outsource its pipeline.** - **Every dosage form under one roof** - the R&D centre in Khatraj develops immediate-release, delayed-release and extended-release tablets, hard and soft gelatin capsules, liquid orals, semi-solids such as creams and gels, small- and large-volume injectables, and oral and topical sprays, covering the full range of formats the company sells. - **Patents that create differentiation** - the company has filed over 25 patent applications and been awarded 7 patents, including inventions for a nasal drug delivery system, a mouth-melting pharmaceutical film, a vaginal suppository composition, and a high-concentration pain-relief formulation, which give it proprietary products beyond plain generics. - **A new dedicated R&D building** - a purpose-built R&D facility was scheduled to begin operations within two to three months of February 2026, expanding the company’s capacity to develop new products and support its growing CDMO pipeline. # Group structure and partners **A single listed entity with two plants, one amalgamated subsidiary, and a clean balance sheet - no debt, and surplus cash deployed in secured inter-corporate deposits.** - **Lincoln Parenteral absorbed** - the company’s former subsidiary Lincoln Parenteral Limited, in which it held 98.58% voting power, was amalgamated into Lincoln Pharmaceuticals under an NCLT-approved scheme with an appointed date of April 1, 2019, consolidating the small-volume injectables business into the parent. - **A residual legal challenge** - minority shareholders holding 1.42% of Lincoln Parenteral filed a petition before the Gujarat High Court, which granted a stay on the implementation of the NCLT amalgamation order, leaving a procedural overhang on the otherwise completed merger. - **Wholly owned entities and related parties** - the company has a 100% subsidiary, Zullinc Healthcare LLP, and enters into related-party transactions for goods, materials and job work with Sunmed Corporation LLP and Shree Corporation. - **Net debt-free with a treasury function** - the company carries no net debt and deploys surplus cash by providing inter-corporate deposits to other companies, secured by assets and mortgages, generating a return on cash that sits between manufacturing cycles.